ClinicalTrials.gg
TerminatedNCT03992196Updated Oct 30, 2023Results posted

A Follow-up Study of Rotigotine Patch in Adolescent Subjects With Restless Legs Syndrome

A Phase 3 interventional study of Rotigotine 1 mg/24 h and Rotigotine 2 mg/24 h in Restless Legs Syndrome, sponsored by UCB Biopharma SRL. Terminated at 1 site in United States. Open to participants aged 13 Years to 17 Years. Per ClinicalTrials.gov, last updated 2023-10-30.

Sponsored by UCB Biopharma SRL (part of UCB S.A.) · Phase 3, Interventional, and Treatment

Why this study was terminated
Sponsor decision; Not a safety decision

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
13 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 19 studies testing rotigotine in Restless Legs Syndrome — none open to participants now, none under way, none of them phase 3. rotigotine · Restless Legs Syndrome.

Enrollment
19th of 19
10 · median 130
Started
2019
the only one that year
Phase 3
10 of 19
none open now
Registered
19th of 19
by date
Lead sponsor
2 of 19
UCB Biopharma SRL

Among the 19 studies testing rotigotine in Restless Legs Syndrome, this one is the 19th largest by enrollment, is the only one that started in 2019, is one of 10 in phase 3, and was the 19th registered.

Restless Legs Syndrome

259 studies on the registry are indexed under Restless Legs Syndrome; 38 are open to participants now.

Browse Restless Legs Syndrome studies →

Open to participants now

None of the 19 studies testing rotigotine in Restless Legs Syndrome is open now. The open studies under Restless Legs Syndrome, anywhere →

About rotigotine

rotigotine: first FDA approval 2007 (NEUPRO), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 25 Restless Legs Syndrome studies recruiting now, 10 (40%) set no upper age limit and 12 (48%) stop at 75 or younger; none take children under 18; 10 take healthy volunteers.

This study: 13 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 19 studies testing rotigotine in Restless Legs Syndrome as a file.
02

Study summary

The purpose of this study is to assess the long-term safety, tolerability and the long-term efficacy of rotigotine treatment in adolescents with idiopathic Restless Legs Syndrome (RLS).

03

Conditions studied

  • Restless Legs Syndrome

Keywords

  • RLS
  • Neupro
  • Rotigotine
04

Who can participate

Ages eligible
13 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject weighs >=40 kg
  • Subject has completed at least one dose step in SP1006, a previous study of rotigotine in adolescents with Restless Legs Syndrome (RLS), without meeting withdrawal criteria
  • Female subjects must be surgically incapable of childbearing, or effectively practicing an acceptable method of (oral/parenteral/implantable hormonal contraceptives, intrauterine device, or barrier and spermicide). Abstinence is an acceptable method. Subjects must agree to use adequate contraception during the study and for 4 weeks after their final dose of study drug
  • Subject is expected to benefit from participation, in the opinion of the investigator

Exclusion criteria

Exclusion Criteria:

  • Subject is experiencing an ongoing serious Adverse Event (SAE) that is assessed to be related to rotigotine by the investigator or Sponsor
  • Subject has active suicidal ideation as indicated by a positive response ("Yes") to either Question 4 or Question 5 of the "Since Last Visit" version of the electronic Columbia Suicide Severity Rating Scale (eC-SSRS) at the final evaluation visit of the previous rotigotine study (ie, Visit 10 of SP1006)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (actual)

Study arms

  • Experimental
    Rotigotine

    Subjects will be initiated on 1 mg/24 h rotigotine and up-titrated to a maximum of 3 mg/24 h rotigotine, with the aim of achieving the individually optimized dosage. Dose adjustment of rotigotine is allowed at any time during the following Maintenance Period up to a maximum dose of 3 mg/24 h. At the end of the Maintenance Period, subjects will be down-titrated.

    Drug: Rotigotine 1 mg/24 h · Drug: Rotigotine 2 mg/24 h · Drug: Rotigotine 3 mg/24 h

Interventions

  • DrugRotigotine 1 mg/24 h

    Drug page: Rotigotine

    Pharmaceutical Form: transdermal patch Route of administration: transdermal use Concentration: Application of rotigotine transdermal patch with 1 mg/24 h (5 cm\^2 patch size).

    Also known as: Neupro

  • DrugRotigotine 2 mg/24 h

    Drug page: Rotigotine

    Pharmaceutical Form: transdermal patch Route of administration: transdermal use Concentration: Application of rotigotine transdermal patch with 2 mg/24 h (10 cm\^2 patch size).

    Also known as: Neupro

  • DrugRotigotine 3 mg/24 h

    Drug page: Rotigotine

    Pharmaceutical Form: transdermal patch Route of administration: transdermal use Concentration: Application of rotigotine transdermal patch with 3 mg/24 h (15 cm\^2 patch size).

    Also known as: Neupro

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Treatment-emergent Adverse Events (TEAEs)

    An adverse event (AE) is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product that does not necessarily have a causal relationship with this treatment. TEAEs were defined as events that started during the Treatment Period or within 30 days following the end of the Treatment Period (ie, on or after the date of first patch application and within 30 days following the date of last patch removal + 1 day), or those events where the intensity worsened within this time frame.

    Time frame: From Baseline until the Safety Follow-Up Visit (up to 14 Months)

  2. Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) Leading to Withdrawal of Study Medication

    An AE is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product that does not necessarily have a causal relationship with this treatment. TEAEs were defined as events that started during the Treatment Period or within 30 days following the end of the Treatment Period (ie, on or after the date of first patch application and within 30 days following the date of last patch removal + 1 day), or those events where the intensity worsened within this time frame.

    Time frame: From Baseline until the Safety Follow-Up Visit (up to 14 Months)

Secondary outcomes

  1. Changes From Baseline in International Restless Legs Rating Scale (IRLS) Sum Score at Visit 9

    The IRLS consisted of 10 questions, each scored using a 5-point scale ranging from 0=not present to 4=very severe. The IRLS sum score was calculated by summing up the single scores of all applicable questions, i.e., the total sum score ranged from 0 (no RLS symptoms present) to 40 (maximum severity in all symptoms). A score between 31 and 40, indicates very severe RLS. A score between 21 and 30 indicates severe RLS. A score between 11 and 20 indicates moderate RLS. A score between 1 and 10 indicates mild RLS and a score of 0 means no RLS. A negative change from Baseline indicates improvement.

    Time frame: Visit 9 (Month 12), compared to Baseline (in SP1006)

  2. Changes From Baseline in Clinical Global Impressions (CGI) Item 1 at Visit 9

    The Clinical Global Impressions Item 1 (Severity of Illness) score ranges from 0 to 7 as follows: 0=not assessed, 1=normal, not ill at all, 2=borderline ill, 3=mildly ill, 4=moderately ill, 5=markedly ill, 6=severely ill, 7=among the most extremely ill. The CGI Item 1 was completed during an interview between the participant and the investigator or designee. A negative change from Baseline indicates improvement.

    Time frame: Visit 9 (Month 12), compared to Baseline (in SP1006)

  3. Changes From Baseline in Restless Legs-6 Rating Scales (RLS-6) at Visit 9

    The RLS-6 Rating Scales was designed to assess the severity of RLS and consisted of 6 subscales. The subscales assessed severity of symptoms at the following times of the day/evening: falling asleep, during the night, during the day at rest, and during the day when engaged in daytime activities (not at rest). In addition, the subscales assessed satisfaction with sleep and severity of daytime tiredness/sleepiness. Scores for each of the 6 subscales ranged from 0 (completely satisfied) to 10 (completely dissatisfied). The change from baseline was derived for each of the subscales and reported in this outcome measure. A negative change from Baseline indicates improvement.

    Time frame: Visit 9 (Month 12), compared to Baseline (in SP1006)

07

Results

Posted Oct 30, 2023

Participant flow

The study started to enroll participants in December 2019 and concluded prematurely in September 2022. Study participants entered this study from the parent rotigotine study in adolescents (SP1006) (NCT03728933).

Enrollment
Participant flow — Enrollment
MilestoneNo TreatmentRotigotine Final Dose 2 mg/24 hRotigotine Final Dose 3 mg/24 h
Started127
Completed027
Not completed100
Withdrew: Lost to follow-up prior dosing100
Treatment
Participant flow — Treatment
MilestoneNo TreatmentRotigotine Final Dose 2 mg/24 hRotigotine Final Dose 3 mg/24 h
Started027
Completed021
Not completed006
Withdrew: Protocol violation001
Withdrew: Poor drug compliance withdrawn by team and sponsor001
Withdrew: Withdrawal due to non-compliance001
Withdrew: Pi's decision due to investigational medicinal product non-compliance001
Withdrew: Withdrawal by parent/guardian002

Outcome measures

PrimaryPercentage of Participants With Treatment-emergent Adverse Events (TEAEs)

An adverse event (AE) is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product that does not necessarily have a causal relationship with this treatment. TEAEs were defined as events that started during the Treatment Period or within 30 days following the end of the Treatment Period (ie, on or after the date of first patch application and within 30 days following the date of last patch removal + 1 day), or those events where the intensity worsened within this time frame.

Time frame:
From Baseline until the Safety Follow-Up Visit (up to 14 Months)
Reported as:
Number · percentage of participants
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs)
percentage of participantsRotigotine Final Dose 2 mg/24 hRotigotine Final Dose 3 mg/24 h
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs)10085.7
PrimaryPercentage of Participants With Treatment-emergent Adverse Events (TEAEs) Leading to Withdrawal of Study Medication

An AE is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product that does not necessarily have a causal relationship with this treatment. TEAEs were defined as events that started during the Treatment Period or within 30 days following the end of the Treatment Period (ie, on or after the date of first patch application and within 30 days following the date of last patch removal + 1 day), or those events where the intensity worsened within this time frame.

Time frame:
From Baseline until the Safety Follow-Up Visit (up to 14 Months)
Reported as:
Number · percentage of participants
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) Leading to Withdrawal of Study Medication
percentage of participantsRotigotine Final Dose 2 mg/24 hRotigotine Final Dose 3 mg/24 h
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) Leading to Withdrawal of Study Medication00
SecondaryChanges From Baseline in International Restless Legs Rating Scale (IRLS) Sum Score at Visit 9

The IRLS consisted of 10 questions, each scored using a 5-point scale ranging from 0=not present to 4=very severe. The IRLS sum score was calculated by summing up the single scores of all applicable questions, i.e., the total sum score ranged from 0 (no RLS symptoms present) to 40 (maximum severity in all symptoms). A score between 31 and 40, indicates very severe RLS. A score between 21 and 30 indicates severe RLS. A score between 11 and 20 indicates moderate RLS. A score between 1 and 10 indicates mild RLS and a score of 0 means no RLS. A negative change from Baseline indicates improvement.

Time frame:
Visit 9 (Month 12), compared to Baseline (in SP1006)
Reported as:
Mean · score on a scale
Changes From Baseline in International Restless Legs Rating Scale (IRLS) Sum Score at Visit 9
score on a scaleRotigotine Final Dose 2 mg/24 hRotigotine Final Dose 3 mg/24 h
Changes From Baseline in International Restless Legs Rating Scale (IRLS) Sum Score at Visit 9NA ± NANA ± NA
SecondaryChanges From Baseline in Clinical Global Impressions (CGI) Item 1 at Visit 9

The Clinical Global Impressions Item 1 (Severity of Illness) score ranges from 0 to 7 as follows: 0=not assessed, 1=normal, not ill at all, 2=borderline ill, 3=mildly ill, 4=moderately ill, 5=markedly ill, 6=severely ill, 7=among the most extremely ill. The CGI Item 1 was completed during an interview between the participant and the investigator or designee. A negative change from Baseline indicates improvement.

Time frame:
Visit 9 (Month 12), compared to Baseline (in SP1006)
Reported as:
Mean · score on a scale
Changes From Baseline in Clinical Global Impressions (CGI) Item 1 at Visit 9
score on a scaleRotigotine Final Dose 2 mg/24 hRotigotine Final Dose 3 mg/24 h
Changes From Baseline in Clinical Global Impressions (CGI) Item 1 at Visit 9NA ± NANA ± NA
SecondaryChanges From Baseline in Restless Legs-6 Rating Scales (RLS-6) at Visit 9

The RLS-6 Rating Scales was designed to assess the severity of RLS and consisted of 6 subscales. The subscales assessed severity of symptoms at the following times of the day/evening: falling asleep, during the night, during the day at rest, and during the day when engaged in daytime activities (not at rest). In addition, the subscales assessed satisfaction with sleep and severity of daytime tiredness/sleepiness. Scores for each of the 6 subscales ranged from 0 (completely satisfied) to 10 (completely dissatisfied). The change from baseline was derived for each of the subscales and reported in this outcome measure. A negative change from Baseline indicates improvement.

Time frame:
Visit 9 (Month 12), compared to Baseline (in SP1006)
Reported as:
Mean · score on a scale
Changes From Baseline in Restless Legs-6 Rating Scales (RLS-6) at Visit 9
score on a scaleRotigotine Final Dose 2 mg/24 hRotigotine Final Dose 3 mg/24 h
Satisfaction with sleepNA ± NANA ± NA
Severity: RLS symptoms at falling asleepNA ± NANA ± NA
Severity: RLS symptoms during the nightNA ± NANA ± NA
Severity: RLS symptoms during the day - at restNA ± NANA ± NA
Severity: RLS symptoms during the day-not at restNA ± NANA ± NA
How tired or sleepy during the dayNA ± NANA ± NA

Adverse events

Collected over From Baseline until the Safety Follow-Up Visit (up to 14 Months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Rotigotine Final Dose 2 mg/24 h0/2 (0%)0/2 (0%)2/2 (100%)
Rotigotine Final Dose 3 mg/24 h0/7 (0%)0/7 (0%)6/7 (85.7%)
Most frequent other events
Showing 10 of 20
Most frequent other events
EventRotigotine Final Dose 2 mg/24 hRotigotine Final Dose 3 mg/24 h
Application site erythemaGeneral disorders2/22/7
Upper respiratory tract infectionInfections and infestations1/21/7
Suspected COVID-19Infections and infestations1/20/7
Procedural dizzinessInjury, poisoning and procedural complications1/20/7
Rhinitis allergicRespiratory, thoracic and mediastinal disorders1/20/7
PruritusSkin and subcutaneous tissue disorders1/21/7
NauseaGastrointestinal disorders0/23/7
Application site rashGeneral disorders0/21/7
HypersensitivityImmune system disorders0/21/7
COVID-19Infections and infestations0/21/7

Baseline characteristics

The Safety Set consisted of all participants who had at least one patch (rotigotine) applied. Due to data protection/data privacy, data cannot be reported for a single participant.

Age, Customized
Age, Customized(Participants)Rotigotine Final Dose 2 mg/24 hRotigotine Final Dose 3 mg/24 hTotal
Adolescents (12-17 years)279
Sex: Female, Male
Sex: Female, Male(Participants)Rotigotine Final Dose 2 mg/24 hRotigotine Final Dose 3 mg/24 hTotal
Female224
Male055
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Rotigotine Final Dose 2 mg/24 hRotigotine Final Dose 3 mg/24 hTotal
Black or African American011
White268
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Rotigotine Final Dose 2 mg/24 hRotigotine Final Dose 3 mg/24 hTotal
Not Hispanic or Latino279
08

Study locations

1 site
  • Rl0007 101
    Culver City, California 90230, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Data from this study may be requested by qualified researchers six months after product approval in the US and/or Europe, or global development is discontinued, and 18 months after trial completion. Investigators may request access to anonymized IPD and redacted study documents which may include: raw datasets, analysis-ready datasets, study protocol, blank case report form, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.clinicalstudydatarequest.com and a signed data sharing agreement will need to be executed. All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal. This plan may change if a determination is made that the data cannot be adequately anonymized.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data from this study may be requested by qualified researchers six months after product approval in the US and/or Europe or global development is discontinued, and 18 months after trial completion.

Access criteria: Qualified researchers may request access to anonymized IPD and redacted study documents which may include: raw datasets, analysis-ready datasets, study protocol, blank case report form, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.clinicalstudydatarequest.com and a signed data sharing agreement will need to be executed. All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal.

Data sharing details ↗ · clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2019 to primary completion in Sep 2022, 32 months.

Results were first posted in Oct 2023, 1 year 1 month after primary completion. A results delay was requested in Aug 2023.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 17, 2019
First posted
Jun 20, 2019
StartActual
Dec 3, 2019
Primary completionActual
Sep 1, 2022
CompletionActual
Sep 1, 2022
Results delay requested
Aug 29, 2023
Results first posted
Oct 30, 2023
Last update
Oct 30, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 30, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03992196
Lead sponsor
UCB Biopharma SRL
Responsible party
Sponsor
First posted
Jun 20, 2019
Start date
Dec 3, 2019
Primary completion
Sep 1, 2022
Completion
Sep 1, 2022
Results posted
Oct 30, 2023
Last update
Oct 30, 2023

Study contacts

UCB Cares
study director · 001 844 599 2273

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rotigotine

Start the discussion